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to 0.886 and they all belonged to 5 factors. There was a strong relationship between 
SCS and EuroQol 5D (r  between 0.46–0.76). CONCLUSIONS: The research sug-
gests that the validity and reliability of the Turkish SCS are satisfactory and that it 
can be used in Turkey.
PRS44
CLINICO-PHARMACOLOGICAL PRESENTATION AND THE OUTCOME 
OF QUALITY OF LIFE OF PATIENTS WITH EXACERBATION OF 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Bawoh M
Yaroslavl State Medical Academy, Yaroslavl, Russia
OBJECTIVES: Determine quality of life of COPD patients. METHODS: The medical 
records of 300 patients with acute exacerbation of COPD who visited City Clinical 
Hospital #2, with mean age 68.5 o 4.5 male and 64.8 o 3.4 female, were retrospec-
tively reviewed. Patients were evaluated on the criteria for COPD [2006]. Socio-
 demographic data, severity of disease, co-morbidity, and use of health resources in 
the previous years were collected. SF-36 quality of life questionnaire were administered 
to all patients. RESULTS: The mean FEV1 value was 45.9 o 9.1%. The severity of the 
disease was mild in 139 (46.3%) cases, moderate in 114 (38.0%), severe in 30 
(10.0%), very severe in 17 (5.7%). With regard to the use of health resources in the 
previous year, the mean values were: visits to physician 7,27 o 1,2 and hospital admis-
sions 8,16 o 0,31. The mean SF-36 scores for patients with mild COPD in the physical 
component before and after therapy were 84.5 o 4.2 and 91.2 o 5.8 with $ % value 
(9.2 o 1.6); moderate 73.2 o 3.1 and 77.6 o 4.6 with $ % value (6.0 o 1.5); severe 
42.2 o 1.2 and 45.2 o 2.6 with $ % (4.5 o 1.4); very severe 19.8 o 2.4 and 23.5 o 
3.8 with $ % value (4.2 o 1.4). Similarly, the mean SF-36 scores on mental component 
of all groups of patients under study, ranging from mild to very severe were 69.60 o 
2.1 and 72.3 o 3.4 with $ % value (3.1 o 2.3); 54.6 o 2.2 and 56.9 o 3.7 with $ % 
value (4.2 o 1.5); 38.0 o 2.3 and 39.6 o 3.1 with $ % 3.9 o 0.8; 28.2 o 1.1 and 29.1 
o 2.4 with $ % value (4.2 o 1.3). CONCLUSIONS: Patients had an increase functional 
dynamic index ($ %) of SF-36 in the physical component, and signiﬁcant reduction 
was only seen in mental component of patients with severe and very severe cases.
RESPIRATORY-RELATED DISORDERS – Health Care Use & Policy Studies
PRS45
CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY 
VENTILATED PATIENTS UNDER DRG 475:  
A POPULATION-BASED STUDY
Bouza C, Lopez T, Sastre M
Carlos III Health Institute, Madrid, Spain
OBJECTIVES: Mechanical ventilation for acute respiratory failure is likely to be a           
reliable indicator of critical care resource requirements on a population level. Our aim 
is to analyze the costs and discharge status for patients with respiratory failure needing 
mechanical ventilation (DRG code 475) in Spain and to examine the impact of age in 
terms of hospital outcome. METHODS: From the 2004 National Hospital Discharge 
Database all records aged 16 years with a ﬁnal DRG 475 were retrieved. This DRG, 
deﬁned as “respiratory system diagnosis with mechanical ventilation”, includes three 
procedure codes and is applied to patients undergoing mechanical ventilation for a 
variable period of time. Demographic characteristics, clinical outcomes and hospital-
resources utilization were examined. An exploratory logistic regression analysis was 
performed to identify factors associated with in-hospital mortality. To depict the 
amount of resources spent to procure a given level of desired outcome (hospital sur-
vival) we determined the cost per survivor based in the average national charges for 
DRG 475. RESULTS: 4267 cases were eligible for analysis. Mean age was 64 yr, 71%            
were men and 85% medical patients. According to Charlson index, 45% of cases had 
no associated comorbidity. Overall 36% of cases required prolonged mechanical 
ventilation. In-hospital mortality was 39%. Median LOS was 14 days. Total hospital 
costs were ª 42,581,929. Multivariate logistic regression showed that age signiﬁcantly 
correlated with in-hospital mortality after adjusting for comorbidities, principal cause 
of hospital admission and duration of mechanical ventilation. An inverse relationship 
between survival rate and age was observed and this resulted in an age-related 
increased cost per survivor. CONCLUSIONS: Age has a signiﬁcant impact on out-      
comes in patients under DRG 475. These analyses will help inform health care deci-
sion-making and resource planning in the face of an ageing population. This study  
has been supported by the Spanish National ID Program (grant number STPY 
1456/07).
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OFF-LABEL PRESCRIBING OF INHALED CORTICOSTEROID/ LONG 
ACTING BETA-AGONIST COMBINATION PRODUCTS IN  
COPD PATIENTS
Rigney U, Emmas C, Morais J
AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: Despite different licences for the use of inhaled corticosteroids/ long 
acting beta—agonist combination products for Chronic Obstructive Pulmonary 
Disease (COPD) and asthma, anecdotal evidence suggests general practitioners pre-
scribe similar formulations and doses for both diseases. For patients with COPD, 
where the licences are more restricted, this may lead to “off-label” prescribing. The 
objective of this study was to examine the frequency and nature of “off-label” pre-
scribing of combination products in COPD patients. METHODS: This was a retro-
spective cohort study using data from the General Practice Research Database 
(GPRD), a large nationally representative UK primary care database. All combined 
salmeterol/ﬂuticasone and formoterol/budesonide prescriptions written between 
Jan 2006 and Dec 2007 for patients with a Read code for COPD were selected. 
“Off-label” prescribing was deﬁned as any formulation and/ or dose of salmeterol/
ﬂuticasone or formoterol/budesonide not licensed for COPD. The proportion of 
“off-label” prescriptions was calculated for each of the 2 treatments and “off-label” 
prescriptions were further subdivided into whether they were “off-label” with respect 
to formulation or dose. All calculations were replicated at the patient level and 
reported in relation to age, sex and smoking status. RESULTS: The analyses were 
based on a total of 21,137 COPD patients receiving combination products (salme-
terol/ﬂuticasone: 17,115; formoterol/budesonide: 4,809) between 2006–2007. 77% of 
prescriptions were “off-label”, 71% for an incorrect formulation and 6% for an 
incorrect dose. 86% of salmeterol/ﬂuticasone prescriptions were “off-label” (85% 
formulation, 1% dose) versus 37% of formoterol/budesonide prescriptions (10% 
formulation, 27% dose). The most frequently prescribed unlicensed formulations 
were salmeterol 25 mcg/ﬂuticasone 250 mcg pMDI (45%) and salmeterol 25 mcg/
ﬂuticasone 125 mcg pMDI (20%). CONCLUSIONS: “Off-label” prescribing of com-
bination therapy in COPD patients is very common in the UK. The impact of off-label 
prescribing on efﬁcacy and patient safety is unknown; “off-label” prescribing poten-
tially represents an economically wasteful prescribing practice.
PRS47
SEASONAL VERSUS NEEDS-BASED IMMUNIZATION SCHEDULES— 
THE EXAMPLE OF RSV
Hampp C, Winterstein AG
University of Florida, Gainesville, FL, USA
OBJECTIVES: Due to cost reaching $10,000/season, respiratory syncytial virus (RSV) 
immunoprophylaxis is limited to high-risk periods, but season determination is heavily 
debated and absolute risk varies signiﬁcantly by geographic location. We present 
monthly RSV incidence rates to estimate absolute burden of disease and numbers 
needed to treat (NNT) to provide an alternative to a dichotomous season deﬁnition. 
METHODS: Medicaid fee-for service recipients 2 years old from California and 
Florida (1999–2004) were selected if they met high-risk criteria for RSV infections 
(chronic lung disease or congenital heart disease based on ICD-9 codes, or prematurity 
up to 32 weeks’ gestational age based on birth certiﬁcates). Monthly RSV hospitaliza-
tion rates were broken down by recipients’ age and adjusted for the effects of immu-
noprophylaxis. NNTs were calculated as inverse of the absolute risk reduction (based 
on relative risk reduction from clinical trial data: 50%). Results in Florida were sepa-
rated in 5 surveillance regions. RESULTS: California showed a very distinct season 
from December–March with almost zero viral activity outside. NNTs were smallest 
in February (50) but increased with increasing age. In Florida, no months had zero 
activity; however, NNTs were never below 125, regardless of age. Among children 1 
year, the lowest NNT was 252 [95% CI: 129–5,875] and NNTs exceeded 500 for 8 
months (January–August). While the northern regions showed a short, distinct season, 
the southern regions experienced prolonged activity, most obvious in the southeast. 
Yet, April through July in the southwest and May/June in the southeast showed NNTs 
exceeding 650 while the winter months had a peak activity that was comparable to 
other regions. CONCLUSIONS: NNTs can address differences in burden of disease 
during the RSV season and between geographic regions and assure equitable access 
to prophylaxis. Reduced RSV incidence in the second year of life should be incorpo-
rated in decisions for immunoprophylaxis.
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A SURVEY OF TOBACCO CESSATION INTERVENTIONS IN THE 
DENTAL SETTING IN JAPAN: NICOTINE REPLACEMENT THERAPY, 
ATTITUDES TOWARDS TOBACCO CESSATION EDUCATION, AND 
BARRIERS TO CESSATION COUNSELING
Nakao H1, Yoshimi I1, Fukuda Y2, Sata F1, Imai H1
1National Institute of Public Health, Wako-shi, Saitama, Japan, 2Yamaguchi University, Ube, 
Yamaguchi, Japan
OBJECTIVES: Tobacco has been identiﬁed as a major risk factor for lung cancer, 
heart disease, and respiratory disease. Adults rarely visit their physicians for preventive 
care. But surveys have shown that more than half of adult smokers see a dentist each 
year for preventive care. This may put dentists in a better position to implement 
tobacco cessation interventions. The aim of the study was to investigate the tobacco 
cessation interventions conducted by dental practitioners in Japan. METHODS: The 
study used a survey mailed to dentists (n  1489) in three prefectures (Tokyo, Iwate, 
Yamanashi) asking about the practitioners’ tobacco cessation activities, patient demo-
graphic characteristics, barriers to counseling, and attitudes towards tobacco in 2008. 
RESULTS: The response rate was 57% (n  847). Dentists advised 22% of patients 
to cease tobacco. More than half of them used a pamphlet or other printed materials. 
However, nicotine replacement therapy was prescribed infrequently (nicotine patches 
in 3.2% and nicotine gum in 2.2% of patients). Asked whether dentists should 
perform tobacco cessation interventions in their ofﬁces, 76% said yes. The main 
barrier to cessation counseling was insufﬁcient time, followed by a lack of knowledge 
and tobacco cessation specialists to whom to refer patients. 85% of respondents had 
no education or training in promoting tobacco cessation. Twenty-two percent of all 
respondents were smokers. CONCLUSIONS: Few dentists perform tobacco cessation 
interventions in their ofﬁces. Nicotine replacement therapy was hardly prescribed at 
all. Dentists have a positive attitude towards tobacco cessation interventions and 
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appear amenable to education and a more active role in performing tobacco cessation 
interventions in their ofﬁces.
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FACTORS RELATED TO STOP SMOKING’S ATTEMPTS AMONG A 
FRENCH COHORT OF SMOKERS: (FOCUS STUDY)
Benhaddi H1, Aubin HJ2, Thomas D3, Stoebner-Delbarre A4, Peiffer G5, Vicaut E6,  
Solesse A1
1Pﬁzer, Paris, France, 2Paul Brousse Hospital, Villejuif, France, 3Cardiology Institut, Paris, 
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6Lariboisière St Louis, Hôpital F. Widal, Paris, France
OBJECTIVES: This study aims at evaluating the attempts to stop smoking and the            
factors related to these attempts in a cohort of smokers followed during 2 years. 
METHODS: A sample of 6032 individuals aged 15 years or more, representative of            
the French population, received a self-administered questionnaire in November 2006. 
Eight hundred and nine smokers were identiﬁed and contacted again in June 2007, 
November 2007, June 2008 and November 2008. A statistical analysis was performed 
on smokers who were reached and interviewed in all phases. RESULTS: In total, 277   
smokers (34%) responded to all interviews. Among them, 10%, 12%, 15%, and 18% 
were quitters in June 2007, November 2007, June 2008, and November 2008, respec-
tively. Seven percent of smokers were consistently quitters at all follow-up interviews. 
Thirty four percent of smokers quitted smoking at least once more than one month 
between two interviews. Smokers who attempted to quit smoking during the follow 
up period (43%) were less dependent to tobacco (p  0.01) and lighter smokers 
(p  0.01). The probability to stop smoking longer than one month decreased in more            
dependant smokers: Odds Ratio  0.77 (CI 95%: 0.67–0.89) and increased in smokers 
with fear of cardiovascular diseases and cancers: Odds Ratio  2.38 (CI 95%: 1.03–
5.50), and medical conditions such as High Blood Pressure, Dyslipidemia, Asthma 
and Diabetes: Odds Ratio  2.42 (CI 95%: 1.10–4.57). Among 42% of smokers who 
declared having intention to stop smoking at the beginning of the study, 50% actually 
did an attempt to quit smoking after a follow up of 2 years. CONCLUSIONS: Half 
of smokers reporting intention to quit did not make an attempt within 2 years. Quit-
ting smoking more than one month was related to dependence to tobacco and current 
health care conditions while fear of smoking-related diseases motivate smokers to quit        
smoking.
URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies
PUK1
USE OF A BAYESIAN MIXED TREATMENT META ANALYSIS TO 
SUPPORT REIMBURSEMENT DECISION MAKING OF PHOSPHATE 
BINDER THERAPY IN END-STAGE RENAL DISEASE
Stevens J1, Keith MS2, Hodgkins P2
1The University of Shefﬁeld, Shefﬁeld, UK, 2Shire Pharmaceuticals, Wayne, PA, USA
OBJECTIVES: Comparative data is routinely preferred by reimbursement decision 
makers. The study objective was to estimate the dose relativity of two non-calcium 
based phosphate binders, lanthanum carbonate (LC) and sevelamer hydrochloride 
(SH) in the treatment of end-stage renal disease (ESRD). METHODS: An indirect 
comparison based on a systematic literature review and Bayesian mixed treatment 
meta-analysis methodology was used to determine the equipotent doses of LC and 
SH. The methodology met Australian Pharmaceutical Beneﬁts Advisory Committee 
standards, a rigorous Health Technology Assessment Agency. The outcome measure 
of interest in ERSD was the mean daily dose required to control serum phosphate at 
target levels. The data were analyzed using WinBUGS software. Posterior results were 
estimated using 25,000 samples after a burn-in of 25,000 iterations and thinning the 
MCMC chain every 25 iterations to account for autocorrelation. Goodness-of-ﬁt was 
also assessed. RESULTS: The literature review identiﬁed nine trials and three treat-
ments comparing LC to calcium (6), SH to calcium (2) and SH to LC (1). An uncon-
strained baseline model using a gamma likelihood for the sample mean doses (and 
sample variances) required to achieve a speciﬁc phosphate reduction and control was 
ﬁtted. An a priori assumption was that the population standard deviations between 
treatments were different. The analysis showed that the dose required to achieve 
phosphate reduction and control was 2.33 (95% Crl: 1.75, 3.01) times greater with 
SH versus LC. The dose relatively is consistent with the ratio calculated using the 
World Health Organization’s deﬁned daily dose for LC and SH. CONCLUSIONS: 
This study illustrates how a mixed-treatment comparison can be used to aid in drug 
therapy decision making when direct head-to-head data is limited. Using this approach, 
the dose relativity ratio of the mean daily dose of sevelamer to the mean daily dose 
of lanthanum carbonate was determined as 2.33.
PUK2
EFFECTIVENESS AND COST-EFFICACY OF PHOSPHATBINDERS IN 
HEMODIALYSIS
Brunner-Ziegler S, Fröschl B, Zsifkovits J
Gesundheit Österreich GmbH, Vienna, Austria
OBJECTIVES: In Germany, 66,508 patients were on haemodialysis because of chronic          
renal insufﬁciency in 2006. Hyperphosphataemia is the strongest independent risk 
factor for mortality in renal patients. Because a reduction in the ingested phosphate 
intake and hemodialysis are not able to reduce serum phosphate concentrations to 
recommended values, phosphate binders (P-binders) are used to bind ingested phos-
phate in the digestive tract. Besides the traditional therapies calcium- and aluminium 
salts, sevelamer and lanthanum are recent developments on the market. The purpose 
of the present Health Technology Assessment (HTA) was to compare the effectiveness, 
safety and economic efﬁciency of different P-binders in chronic renal insufﬁcient 
patients. METHODS: The systematic literature search yielded 1251 abstracts. Follow-       
ing a two-part selection process with predeﬁned criteria 18 publications were included 
into the assessment. RESULTS: All P-binders effectively controlled serum phosphate,      
calcium and intact parathyroid hormone concentrations. The number of hypercal-
cemic episodes were higher when using calcium-containing P-binders compared to 
sevelamer and lanthanum. Regarding mortality rate, cardiovascular artery calciﬁcation 
and bone metabolism no deﬁnite conclusions could be drawn. Economic studies 
showed higher costs for sevelamer and lanthanum compared to calcium-containing 
P-binders. CONCLUSIONS: The validity of the present HTA is limited due to the           
limited number of available publications, the low sample size of treated patients and 
the fact that the majority of studies were funded by industry and are based on the 
same patient collectives. From a medical point of view, sevelamer showed superiority 
over calcium-containing P-binders at least for special indications.
PUK3
FORECASTING SPANISH RENAL REPLACEMENT THERAPY TRENDS 
FROM REGISTRY DATA: A QUANTILE REGRESSION APPROACH
Villa G, Cuervo J, Ortiz LF, Rebollo P
BAP Health Outcomes Research, Oviedo, Asturias, Spain
OBJECTIVES: To forecast Spanish Renal Replacement Therapy (RRT) trends from 
registry data. METHODS: In Spain, RRT ﬁgures are published yearly by the Spanish 
Nephrology Society (Spanish acronym, SEN) registry. States described include hemo-
dialysis (HD), peritoneal dialysis (PD), and transplant (TX). Both incidence and preva-
lence ﬁgures are provided. The SEN registry gathers data from several regional 
registries. However, an unbalanced panel is faced, as some relevant registries enter or 
exit the analysis from year to year. Drop-outs make SEN ﬁgures highly volatile and 
impractical for epidemiologic or economic studies. Firstly, original data from the SEN 
registry were collected and weighted in order to account for the whole Spanish popula-
tion. Secondly, either linear or quadratic trends were ﬁtted by non-parametric Quantile 
Regression (QR) with bootstrapped standard errors. QR is suitable in the case of tailed 
distributed dependent variables and in the presence of outliers, since it predicts the 
conditional median of the response, instead of its conditional mean (Ordinary Least 
Squares approach). Finally, forecasted RRT ﬁgures were provided and compared to 
the registered data. RESULTS: Weighted Spanish RRT registry data presented strongly 
signiﬁcant trends in the period 1996/2007, as shown by graphical analyses, trend 
coefﬁcients signiﬁcance (p  0.05), and goodness-of-ﬁt of QRs. Positive trends were 
found in HD (R2  0.718), PD (R2  0.538), and TX (R2  0.692) prevalences; and 
in HD (R2  0.719, quadratic), PD (R2  0.526), and TX (R2  0.535) incidences. 
Overall, the predictive performance of the regression models considered was good. 
CONCLUSIONS: SEN registry weighted RRT data display strongly signiﬁcant trends, 
during the period of study, as shown by both graphic analyses and QRs results. Fore-
casted RRT ﬁgures are very useful in epidemiologic or economic studies, overcoming 
the problems, namely the high volatility, observed in published registry data.
URINARY/KIDNEY DISORDERS – Cost Studies
PUK4
THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO 
CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS 
IN THE PUBLIC HEALTH CARE SYSTEM IN BRAZIL
Saggia MG
Roche Brazil, Sao Paulo, SP, Brazil
OBJECTIVES: To evaluate the impact on costs of treating complications derived from 
chronic kidney disease (CKD) in patients undergoing hemodialysis in the public health 
care system in Brazil. METHODS: Owing to the lack of local databases, a survey with 
experts was conducted to collect data about the main causes of hospital admissions 
which resulted from complications during the dialysis period of CKD patients. A group 
of 600 patients from reference centers in Brazil was studied. Later, the experts 
answered to a questionnaire about the procedures needed to manage complications. 
Then, a micro-costing was performed, only direct costs were considered: length of 
staying, medical procedures, physician fees and drugs. Sources used for costing were: 
SAI/SIH—SUS (the government reimbursement procedures list), Revista Kairos 
(January 2009) (drugs price list) and Guia Farmacêutico Brasíndice (January 2009) 
(materials price list). The time horizon of this analysis was 1 year, thus no discount 
rate was assumed. The perspective assumed was that of the public payer. RESULTS: 
The 3 most frequent causes of hospital admissions and their respective costs in the 
studied centers were: cardiac complications (33.27%; R$2789); infections (31.90%; 
R$3113); and venous access complications (9.20%; R$2183). For an average patient, 
the total costs in 1 year of treatment were estimated to be R$4358. CONCLUSIONS: 
This study suggests that for the 600 patients studied group the economic impact for 
the public payer with hospital admissions caused by CKD complications is signiﬁcant 
being as high as R$ 2,615,331 in one year.
